07:00 , Jul 19, 2010 |  BioCentury  |  Finance

Rationalizing DeveloGen

A total of $61.1 million in venture money went into DeveloGen AG in its three financing rounds from 1998-2004, but Evotec AG (Xetra:EVT) will get the metabolic and endocrine company for no more than €14...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Ebb & Flow

Amgen has shed $61 billion, or 58% of its market cap, over the last three and a half years and last week found itself slipping into third place among top tier biotechs, giving up the...
08:00 , Feb 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Encysive (NASDAQ:ENCY) has never disclosed exactly what the FDA doesn't like about the company's Phase III data on Thelin sitaxsentan , which has received three FDA approvable letters for pulmonary arterial hypertension (PAH) despite already...
08:00 , Dec 10, 2007 |  BioCentury  |  Finance

Ebb & Flow

Genentech shares hit their lowest level since early 2005 last week, shedding $7.76 (10%) to reach $68.49 and lopping off more than $8 billion of the company's market cap to $72 billion. The dive came...
07:00 , Mar 12, 2007 |  BioCentury  |  Finance

Too much money

In 2002, MPM Capital closed what was the largest-ever dedicated healthcare fund. At $940 million, BioVentures III was intended to allow the firm to put its capital to work in $50-$100 million chunks as part...
01:20 , Mar 6, 2007 |  BC Extra  |  Financial News

MPM Capital closes $550 million fund

MPM Capital closed its MPM BioVentures IV at $550 million. MPM said 85% of the fund will be invested in biotech and specialty pharmaceuticals, with the remainder going to medtech, tools and diagnostics. MPM expects...
07:00 , Sep 25, 2006 |  BioCentury  |  Strategy

Midcap wake-up call

For years, it has been an open secret that many of Europe's family-owned mid-cap pharmas have been lost at sea, unable to adapt to the new world of innovative in-house R&D and aggressive in-licensing. Merck...
07:00 , Jun 19, 2006 |  BioCentury  |  Finance

Ebb & Flow

Investors gave a cool response to Intercell’s news that it had signed a deal covering its Japanese encephalitis vaccine with Novartis (NVS; SWX:NOVN). The agreement includes milestones up to E37 million ($46.7 million) split almost...
07:00 , May 8, 2006 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe U.S. investment in Europe European venture rounds in excess of $30 million in the past year. Selected firms that do not list a major office in Europe are in boldface. Temasek...